Intercept Pharmaceuticals, Inc. Logo

Press releases

Date Title and Summary View
Toggle Summary Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering New York, NY, September 4, 2012 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat
View HTML
Toggle Summary Intercept Pharmaceuticals Closes $30 Million Series C Financing
OrbiMed’s Jonathan Silverstein and Klaus Veitinger Join Board of Directors
View HTML
Toggle Summary Intercept Pharmaceuticals and Servier Announce Agreement for Intercept's TGR5 Research Program in Type 2 Diabetes View HTML
Toggle Summary Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis View HTML
Toggle Summary Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease View HTML
Toggle Summary Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals Obeticholic Acid View HTML
Toggle Summary Intercept Pharmaceuticals Presents Positive Phase II Results from Study of INT-747 Therapy in Primary Biliary Cirrhosis at EASL
Company Also Presents Data on Novel Dual FXR/TGR5 Agonist INT-767
View HTML
Toggle Summary Intercept Pharmaceuticals Raises $25 Million Series B Financing
Dr. Lorenzo Tallarigo Appointed Chairman
View HTML
Toggle Summary Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment of Primary Biliary Cirrhosis View HTML
Toggle Summary Intercept Pharmaceuticals’ FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
Company to Present Data at EASD Plenary Session
View HTML